The effect of sumatriptan on cephalic arteries: A 3T MR-angiography study in healthy volunteers

Cephalalgia

Volumn 33, Issue 12, 2013, Pages 1009-1016

  Amin, Faisal Mohammad ^a   Asghar, Mohammad Sohail ^a   Ravneberg, Julie W ^a   De Koning, Patrick J ^b   Larsson, Henrik B ^a   Olesen, Jes ^a   Ashina, Messoud ^a  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

arteries; blood brain barrier; migraine; MR angiography; Sumatriptan; vasoconstriction

Indexed keywords

SUMATRIPTAN; SUMATRIPTAN SUCCINATE; SEROTONIN 1 AGONIST;

ADULT; ARTERY CONSTRICTION; ARTERY DIAMETER; ARTICLE; BASILAR ARTERY; BLOOD BRAIN BARRIER; BLOOD OXYGEN TENSION; BREATHING; CARBON DIOXIDE TENSION; CLINICAL ARTICLE; COMMON CAROTID ARTERY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; HEART RATE; HUMAN; INTERNAL CAROTID ARTERY; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE CEREBRAL ARTERY; MIDDLE MENINGEAL ARTERY; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE SCANNER; SUPERFICIAL TEMPORAL ARTERY; SYSTOLIC BLOOD PRESSURE; BRAIN ARTERY; CONTROLLED STUDY; DRUG EFFECTS; MUSCLE CONTRACTION; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; VASCULAR SMOOTH MUSCLE; YOUNG ADULT;

ADULT; CEREBRAL ARTERIES; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SUMATRIPTAN; YOUNG ADULT;

EID: 84881134215     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102413483374     Document Type: Article

References (26)

1. Olesen J, Ashina M. Emerging migraine treatments and drug targets. Trends Pharmacol Sci. 2011 ; 32: 352-359
2. Ferrari MD, Melamed E, Gawel MJ, et al. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991 ; 325: 316-321
3. Tfelt-Hansen PC. Does sumatriptan cross the blood-brain barrier in animals and man?. J Headache Pain. 2010 ; 11: 5-12
4. Ahn AH, Basbaum AI. Where do triptans act in the treatment of migraine?. Pain. 2005 ; 115: 1-4
5. Humphrey PPA, Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci. 1991 ; 12: 444-446
6. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - Current understanding and treatment. N Engl J Med. 2002 ; 346: 257-270
7. Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the action of 5HT1B/1D receptor agonists. Proc Natl Acad Sci USA. 2004 ; 101: 4274-4279
8. Asghar MS, Hansen AE, Amin FM, et al. Evidence for a vascular factor in migraine. Ann Neurol. 2011 ; 69: 635-645
9. Asghar MS, Hansen AE, Kapijimpanga T, et al. Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers. Neurology. 2010 ; 75: 1520-1526
10. de Koning PJ, Schaap JA, Janssen JP, et al. Automated segmentation and analysis of vascular structures in magnetic resonance angiographic images. Magn Reson Med. 2003 ; 50: 1189-1198
11. Jansen I, Olesen J, Edvinsson L. 5-Hydroxytryptamine receptor characterization of human cerebral, middle meningeal and temporal arteries: Regional differences. Acta Physiol Scand. 1993 ; 147: 141-150
12. Parsons AA, Whalley ET, Feniuk W, et al. 5-HT1-like receptors mediate 5-hydroxytryptamine-induced contraction of human isolated basilar artery. Br J Pharmacol. 1989 ; 96: 434-449
13. Silva SA, Marques FB, Ribeiro CAF. Characterization of the human basilar artery contractile response to 5-HT and triptans. Fundam Clin Pharmacol. 2007 ; 21: 265-272
14. Parssons AA, Raval P, Smith S, et al. Effects of the novel high-affinity 5-HT(1B/1D)-receptor ligand frovatriptan in human isolated basilar and coronary arteries. J Cardiovasc Pharmacol. 1998 ; 32: 220-224
15. Bou J, Gras J, Cortijo J, et al. Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries. Cephalalgia. 2001 ; 21: 804-812
16. Hardebo JE. Vasoreactivity of the intracranial carotid artery. Cephalalgia. 1992 ; 12: 280-283
17. Duvernoy HM, Risold PY. The circumventricular organs: An atlas of comparative anatomy and vascularization. Brain Res Rev. 2007 ; 56: 119-147
18. Nilsson T, Longmore J, Shaw D, et al. Contractile 5-HT1B receptors in human cerebral arteries: Pharmacological characterization and localization with immunocytochemistry. Br J Pharmacol. 1999 ; 128: 1133-1140
19. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995 ; 1: 658-660
20. Limmroth V, May A, Auerbach P, et al. Changes in cerebral blood flow velocity after treatment with sumatriptan or placebo and implications for the pathophysiology of migraine. J Neurol Sci. 1996 ; 138: 60-65
21. Amin FM, Asghar MS, Guo S, et al. Headache and prolonged dilatation of the middle meningeal artery PACAP38 in healthy volunteers. Cephalalgia. 2012 ; 32: 140-149
22. Henkes H, May A, Kühne D, et al. Sumatriptan: Vasoactive effect on human dural vessels, demonstrated by subselective angiography. Cephalalgia. 1996 ; 16: 224-230
23. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004 ; 350: 1104-1110
24. Villalón CM, Olesen J. The role of CGRP in pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther. 2009 ; 124: 309-323
25. Tfelt-Hansen PC, Olesen J. The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: A review of two placebo-controlled phase II trials. J Headache Pain. 2012 ; 13: 271-275
26. Jakubowski M, Levy D, Goor-Aryeh I, et al. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache. 2005 ; 45: 850-861